GoodRx - GDRX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $8.78
Forecasted Upside: 26.12%
Number of Analysts: 19
Breakdown:
1 Sell Ratings
8 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$6.96 As of 04/24/2024 01:00 AM ET

▼ -0.01 (-0.14%)

1 month | 3 months | 12 months

Get New GoodRx Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GDRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GDRX

^$8.78

▲ +26.12% Upside Potential

This price target is based on 19 analysts offering 12 month price targets for GoodRx in the last 3 months. The average price target is $8.78, with a high forecast of $14.00 and a low forecast of $4.50. The average price target represents a 26.12% upside from the last price of $6.96.

Current Consensus is Hold

The current consensus among 19 investment analysts is to hold stock in GoodRx. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

11/2/2022

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

1/31/2023

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

5/1/2023

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

7/30/2023

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

10/28/2023

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

1/26/2024

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

3/26/2024

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

4/25/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2024	KeyCorp	Upgrade	Sector Weight ➝ Overweight	$9.00	Low
3/25/2024	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$7.50 ➝ $10.00	Low
3/1/2024	Wells Fargo & Company	Boost Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $7.50	Low
3/1/2024	UBS Group	Boost Target	Neutral ➝ Neutral	$5.00 ➝ $8.00	Low
3/1/2024	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$7.00 ➝ $8.00	Low
3/1/2024	The Goldman Sachs Group	Boost Target	Neutral ➝ Neutral	$6.50 ➝ $7.50	Low
3/1/2024	TD Cowen	Boost Target	Outperform ➝ Outperform	$12.00 ➝ $14.00	Low
3/1/2024	Truist Financial	Boost Target	Hold ➝ Hold	$7.50 ➝ $8.00	Low
3/1/2024	Barclays	Boost Target	Overweight ➝ Overweight	$8.00 ➝ $9.00	Low
3/1/2024	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$7.00 ➝ $10.00	Low
2/26/2024	Leerink Partnrs	Reiterated Rating	Outperform		Low
2/26/2024	SVB Leerink	Initiated Coverage	Outperform	$8.00	Low
1/16/2024	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $7.00	Low
1/12/2024	Truist Financial	Boost Target	Hold ➝ Hold	$5.50 ➝ $7.50	Low
1/2/2024	Bank of America	Downgrade	Buy ➝ Underperform	$8.00 ➝ $4.50	Low
11/17/2023	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$7.00 ➝ $6.00	Low
11/10/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.50	Low
11/10/2023	Truist Financial	Lower Target	Hold ➝ Hold	$8.00 ➝ $5.50	Low
11/10/2023	The Goldman Sachs Group	Lower Target	Neutral ➝ Neutral	$7.00 ➝ $6.00	Low
11/10/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$8.00 ➝ $5.00	Low
9/14/2023	JPMorgan Chase & Co.	Boost Target	Neutral ➝ Neutral	$6.00 ➝ $7.00	Low
8/10/2023	JPMorgan Chase & Co.	Boost Target	Neutral ➝ Neutral	$5.00 ➝ $6.00	Low
8/10/2023	Guggenheim	Boost Target	Buy ➝ Buy	$8.00 ➝ $10.00	Low
8/10/2023	Deutsche Bank Aktiengesellschaft	Boost Target	Hold ➝ Hold	$6.00 ➝ $8.00	Low
8/10/2023	Credit Suisse Group	Boost Target	Neutral ➝ Neutral	$7.00 ➝ $8.00	Low
8/10/2023	The Goldman Sachs Group	Boost Target	Neutral ➝ Neutral	$6.25 ➝ $7.00	Low
8/10/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$6.00 ➝ $8.00	Low
8/10/2023	Evercore ISI	Boost Target	In-Line ➝ In-Line	$7.00 ➝ $10.00	Low
8/10/2023	Citigroup	Boost Target	Buy ➝ Buy	$7.00 ➝ $11.00	Low
8/10/2023	DA Davidson	Upgrade	Neutral ➝ Buy	$9.50	Low
8/9/2023	Wells Fargo & Company	Boost Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $7.00	Low
7/31/2023	TD Cowen	Upgrade	Market Perform ➝ Outperform	$6.50 ➝ $12.00	Low
7/18/2023	Truist Financial	Boost Target	Hold	$6.00 ➝ $7.00	Low
7/17/2023	Morgan Stanley	Boost Target		$6.00 ➝ $8.00	Low
5/11/2023	Deutsche Bank Aktiengesellschaft	Lower Target		$8.00 ➝ $6.00	Low
5/11/2023	Bank of America	Lower Target		$9.00 ➝ $8.00	Low
3/8/2023	Citigroup	Boost Target	Buy	$7.00 ➝ $7.50	Low
3/7/2023	Deutsche Bank Aktiengesellschaft	Boost Target	Hold	$7.00 ➝ $8.00	Low
3/2/2023	Credit Suisse Group	Lower Target	Neutral	$9.00 ➝ $8.00	Low
3/1/2023	Wells Fargo & Company	Boost Target	Equal Weight	$5.50 ➝ $6.00	Low
3/1/2023	The Goldman Sachs Group	Lower Target	Neutral	$8.00 ➝ $7.00	Low
1/18/2023	Barclays	Lower Target	Overweight	$9.00 ➝ $8.00	Low
12/1/2022	Citigroup	Initiated Coverage	Buy	$7.00	Low
11/16/2022	Truist Financial	Lower Target		$6.00	N/A
11/16/2022	Cowen	Lower Target		$6.50	N/A
11/15/2022	DA Davidson	Lower Target		$5.00	Low
11/10/2022	Deutsche Bank Aktiengesellschaft	Lower Target		$9.00 ➝ $7.00	Low
11/9/2022	The Goldman Sachs Group	Lower Target	Neutral	$10.00 ➝ $8.00	Low
11/9/2022	Morgan Stanley	Lower Target	Equal Weight	$10.00 ➝ $6.00	Low
11/9/2022	Royal Bank of Canada	Lower Target	Sector Perform	$11.00 ➝ $6.00	Low
11/4/2022	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$10.00 ➝ $8.00	N/A
10/11/2022	Barclays	Lower Target	Overweight	$13.00 ➝ $9.00	Low
9/15/2022	KeyCorp	Initiated Coverage	Sector Weight ➝ Sector Weight		Low
9/7/2022	Truist Financial	Initiated Coverage	Hold	$6.50	Low
8/15/2022	Evercore ISI	Boost Target		$12.00	N/A
8/12/2022	DA Davidson	Initiated Coverage	Neutral	$8.00	Low
8/10/2022	Morgan Stanley	Lower Target	Equal Weight	$10.50 ➝ $10.00	Low
8/9/2022	SVB Leerink	Boost Target	Market Perform	$8.00 ➝ $11.00	Low
8/9/2022	Credit Suisse Group	Boost Target	Neutral	$10.00 ➝ $11.00	Low
8/9/2022	The Goldman Sachs Group	Boost Target	Neutral	$9.00 ➝ $10.00	Low
8/9/2022	Royal Bank of Canada	Boost Target	Sector Perform	$6.50 ➝ $11.00	Low
8/9/2022	Barclays	Boost Target	Overweight	$12.00 ➝ $13.00	Low
7/20/2022	Barclays	Lower Target	Overweight	$15.00 ➝ $12.00	Low
7/18/2022	Guggenheim	Lower Target	Buy	$17.00 ➝ $13.00	Low
6/23/2022	Royal Bank of Canada	Reiterated Rating	Sector Perform	$8.00 ➝ $6.50	Low
6/22/2022	Robert W. Baird	Lower Target	Neutral	$7.00 ➝ $6.00	Low
6/13/2022	Cowen	Lower Target	Market Perform	$22.00 ➝ $9.00	Low
6/13/2022	Cowen	Lower Target		$22.00 ➝ $9.00	High
6/9/2022	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$12.00 ➝ $9.00	High
6/6/2022	Bank of America	Initiated Coverage	Buy ➝ Buy	$11.00	Medium
6/1/2022	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $7.00	Medium
5/20/2022	Morgan Stanley	Lower Target	Equal Weight	$19.00 ➝ $10.50	Low
5/12/2022	Wells Fargo & Company	Lower Target		$20.00 ➝ $9.00	High
5/11/2022	Deutsche Bank Aktiengesellschaft	Lower Target		$20.00 ➝ $10.00	High
5/11/2022	Credit Suisse Group	Lower Target		$22.00 ➝ $10.00	High
5/10/2022	Barclays	Lower Target		$28.00 ➝ $15.00	High
5/10/2022	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$33.00 ➝ $10.00	High
5/10/2022	Raymond James	Downgrade	Outperform ➝ Market Perform		High
5/10/2022	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$35.00 ➝ $8.00	High
4/11/2022	Wells Fargo & Company	Initiated Coverage	Equal Weight	$20.00	Low
4/6/2022	Guggenheim	Initiated Coverage	Buy	$24.00	Low
4/5/2022	Robert W. Baird	Boost Target		$17.00 ➝ $23.00	N/A
3/17/2022	Credit Suisse Group	Lower Target	Neutral	$27.00 ➝ $22.00	High
3/15/2022	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$17.00	High
3/8/2022	Barclays	Lower Target	Overweight	$35.00 ➝ $28.00	Medium
3/2/2022	Morgan Stanley	Lower Target	Equal Weight	$41.00 ➝ $19.00	High
3/2/2022	Raymond James	Lower Target	Outperform	$45.00 ➝ $30.00	High
3/2/2022	Deutsche Bank Aktiengesellschaft	Lower Target	Hold	$25.00 ➝ $20.00	High
3/1/2022	JPMorgan Chase & Co.	Lower Target	Underweight	$33.00 ➝ $20.00	High
3/1/2022	Evercore ISI	Lower Target	Outperform	$47.00 ➝ $28.00	High
3/1/2022	Bank of America	Lower Target	Neutral	$42.00 ➝ $28.00	High
3/1/2022	The Goldman Sachs Group	Lower Target	Buy	$43.00 ➝ $30.00	High
3/1/2022	SVB Leerink	Lower Target	Outperform	$49.00 ➝ $33.00	High
3/1/2022	Royal Bank of Canada	Lower Target	Outperform	$50.00 ➝ $35.00	High
3/1/2022	Barclays	Lower Target	Overweight	$43.00 ➝ $35.00	High
3/1/2022	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$41.00 ➝ $27.00	High
3/1/2022	Cowen	Downgrade	Outperform ➝ Market Perform	$49.00 ➝ $22.00	High
1/25/2022	Deutsche Bank Aktiengesellschaft	Lower Target		$44.00 ➝ $25.00	Medium
1/7/2022	The Goldman Sachs Group	Initiated Coverage	Buy	$43.00	High
1/5/2022	Robert W. Baird	Lower Target		$40.00 ➝ $34.00	High
12/21/2021	Stephens	Initiated Coverage	Overweight	$45.00	High
12/17/2021	Morgan Stanley	Boost Target	Equal Weight	$38.00 ➝ $41.00	Low
12/1/2021	Jefferies Financial Group	Initiated Coverage	Buy	$47.00	High
11/15/2021	Deutsche Bank Aktiengesellschaft	Lower Target	Hold	$47.00 ➝ $44.00	Medium
11/11/2021	Barclays	Boost Target	Overweight	$45.00 ➝ $47.00	Medium
11/11/2021	SVB Leerink	Lower Target	Outperform ➝ Outperform	$56.00 ➝ $49.00	Medium
10/1/2021	Deutsche Bank Aktiengesellschaft	Boost Target	Hold	$37.00 ➝ $47.00	High
9/14/2021	Credit Suisse Group	Boost Target	Outperform	$45.00 ➝ $52.00	Low
8/31/2021	Barclays	Upgrade	Equal Weight ➝ Overweight	$45.00	Medium
8/24/2021	Cowen	Lower Target	Outperform	$44.00 ➝ $42.00	High
8/15/2021	SVB Leerink	Initiated Coverage	Buy	$56.00	High
8/13/2021	Raymond James	Upgrade	Market Perform ➝ Outperform	$45.00	Medium
7/2/2021	Morgan Stanley	Boost Target	Equal Weight	$36.00 ➝ $38.00	Low
5/27/2021	Robert W. Baird	Initiated Coverage	Neutral	$37.00	Low
5/18/2021	Credit Suisse Group	Lower Target	Outperform ➝ Outperform	$50.00 ➝ $45.00	Low
5/14/2021	SVB Leerink	Lower Target	Outperform	$61.00 ➝ $56.00	High
5/14/2021	Royal Bank of Canada	Lower Target	Outperform	$56.00 ➝ $50.00	High
5/14/2021	Barclays	Lower Target	Equal Weight	$43.00 ➝ $33.00	High
5/14/2021	Citigroup	Boost Target	Buy	$53.00 ➝ $70.00	High
5/10/2021	Cowen	Lower Target	Outperform	$70.00 ➝ $58.00	High
3/15/2021	Credit Suisse Group	Boost Target	Outperform	$49.00 ➝ $50.00	Low
3/12/2021	Barclays	Boost Target		$35.00 ➝ $45.00	Low
3/12/2021	Deutsche Bank Aktiengesellschaft	Boost Target	Hold	$31.00 ➝ $37.00	High
3/4/2021	SVB Leerink	Reiterated Rating	Buy	$61.00	Medium
2/12/2021	Cowen	Boost Target	Outperform	$50.00 ➝ $70.00	Low
1/25/2021	Guggenheim	Initiated Coverage	Buy	$52.00	High
11/23/2020	The Goldman Sachs Group	Lower Target	Neutral	$49.00 ➝ $44.00	Low
11/20/2020	Credit Suisse Group	Lower Target	Outperform	$60.00 ➝ $49.00	Low
11/19/2020	Barclays	Lower Target	Equal Weight	$55.00 ➝ $35.00	High
11/19/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$56.00	High
11/18/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$36.00	Low
11/18/2020	JPMorgan Chase & Co.	Reiterated Rating	Neutral ➝ Underweight	$29.00	Low
11/18/2020	Deutsche Bank Aktiengesellschaft	Lower Target	Hold	$50.00 ➝ $31.00	High
11/17/2020	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$29.00	High
10/19/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$48.00	High
10/19/2020	Cowen	Initiated Coverage	Outperform	$63.00	High
10/19/2020	Morgan Stanley	Initiated Coverage	Overweight	$57.00	High
10/19/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral	$59.00	High
10/19/2020	Raymond James	Initiated Coverage	Equal Weight ➝ Market Perform	$57.00 ➝ $61.00	High
10/19/2020	Credit Suisse Group	Initiated Coverage	Outperform	$60.00	High
10/19/2020	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$50.00	High
10/19/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$55.00	High
10/19/2020	Bank of America	Initiated Coverage	Neutral	$58.00	High
10/19/2020	UBS Group	Initiated Coverage	Buy	$64.00	High
10/19/2020	Barclays	Initiated Coverage	Equal Weight	$53.00	High
10/19/2020	SVB Leerink	Initiated Coverage	Outperform	$61.00	High

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

6 very positive mentions
7 positive mentions
0 negative mentions
2 very negative mentions

Mentions as of

9/28/2023

2 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/28/2023

3 very positive mentions
7 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

11/27/2023

5 very positive mentions
7 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/27/2023

13 very positive mentions
11 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

1/26/2024

4 very positive mentions
12 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/25/2024

13 very positive mentions
26 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

3/26/2024

3 very positive mentions
17 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Today's Range

Now: $6.96

$6.84

$7.13

50 Day Range

MA: $6.91

$6.38

$8.35

52 Week Range

Now: $6.96

$4.14

$9.37

Volume

608,872 shs

Average Volume

904,593 shs

Market Capitalization

$2.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of GoodRx?: The following Wall Street research analysts have issued reports on GoodRx in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, DA Davidson, Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, JPMorgan Chase & Co., KeyCorp, Leerink Partnrs, Morgan Stanley, Royal Bank of Canada, SVB Leerink LLC, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for GDRX.
What is the current price target for GoodRx?: 18 Wall Street analysts have set twelve-month price targets for GoodRx in the last year. Their average twelve-month price target is $8.78, suggesting a possible upside of 26.1%. TD Cowen has the highest price target set, predicting GDRX will reach $14.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $4.50 for GoodRx in the next year.
View the latest price targets for GDRX.
What is the current consensus analyst rating for GoodRx?: GoodRx currently has 1 sell rating, 8 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GDRX, but not buy more shares or sell existing shares.
View the latest ratings for GDRX.
What other companies compete with GoodRx?: Other companies that are similar to GoodRx include ACADIA Pharmaceuticals, Olink Holding AB (publ), MoonLake Immunotherapeutics, PROCEPT BioRobotics and MorphoSys. Learn More about companies similar to GoodRx.
How do I contact GoodRx's investor relations team?: GoodRx's physical mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The company's listed phone number is 855-268-2822 and its investor relations email address is [email protected]. The official website for GoodRx is www.goodrx.com. Learn More about contacing GoodRx investor relations.

GoodRx - GDRX Stock Price Target and Predictions

Analyst Price Target for GDRX

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.27 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of GoodRx?

What is the current price target for GoodRx?

What is the current consensus analyst rating for GoodRx?

What other companies compete with GoodRx?

How do I contact GoodRx's investor relations team?